# Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

> **NCT05470413** · PHASE3 · UNKNOWN · sponsor: **Reistone Biopharma Company Limited** · enrollment: 330 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **DRUG:** SHR0302
- **DRUG:** SHR0302
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05470413
- **Lead sponsor:** Reistone Biopharma Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-18
- **Primary completion:** 2023-10-31
- **Final completion:** 2024-02-15
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05470413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05470413, "Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05470413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*